Fmr LLC Sells 456,524 Shares of Bruker Co. (NASDAQ:BRKR)

FMR LLC trimmed its position in Bruker Co. (NASDAQ:BRKR - Free Report) by 3.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,849,598 shares of the medical research company's stock after selling 456,524 shares during the quarter. FMR LLC owned 9.14% of Bruker worth $811,863,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Captrust Financial Advisors bought a new position in shares of Bruker in the third quarter worth about $311,000. Jacobs Levy Equity Management Inc. acquired a new position in Bruker during the 3rd quarter worth approximately $313,000. Quantinno Capital Management LP bought a new position in Bruker in the 3rd quarter valued at approximately $268,000. State Street Corp boosted its position in Bruker by 9.6% in the third quarter. State Street Corp now owns 3,627,300 shares of the medical research company's stock valued at $250,501,000 after buying an additional 318,808 shares in the last quarter. Finally, National Bank of Canada FI grew its stake in shares of Bruker by 0.3% during the third quarter. National Bank of Canada FI now owns 94,867 shares of the medical research company's stock worth $6,551,000 after buying an additional 318 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Guggenheim reissued a "buy" rating on shares of Bruker in a report on Monday, February 24th. Citigroup cut their price target on Bruker from $75.00 to $50.00 and set a "buy" rating on the stock in a research note on Monday, April 7th. Stifel Nicolaus dropped their price objective on shares of Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a report on Friday, February 14th. Finally, Barclays cut their target price on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Thursday. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $66.50.

Remove Ads

Bruker Trading Up 1.8 %

Shares of NASDAQ BRKR traded up $0.69 during midday trading on Friday, reaching $38.76. The stock had a trading volume of 3,139,890 shares, compared to its average volume of 1,467,987. The company's 50 day moving average price is $46.16 and its 200 day moving average price is $54.75. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. Bruker Co. has a twelve month low of $34.10 and a twelve month high of $90.03. The firm has a market cap of $5.88 billion, a price-to-earnings ratio of 51.00, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, topping analysts' consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. As a group, sell-side analysts expect that Bruker Co. will post 2.69 EPS for the current year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date was Monday, March 17th. Bruker's payout ratio is 26.32%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.